Abstract | PURPOSE: METHODS: Thirty-one patients with GCC-positive, advanced gastrointestinal cancers received intravenous TAK-164 on day 1 of 21-day cycles. Dose escalation proceeded based on cycle 1 safety data via a Bayesian model. RESULTS: Median age was 58 years (range 32-72), 25 patients (80.6%) had colorectal carcinoma, and median number of prior therapies was four. No dose-limiting toxicities (DLTs) were reported during cycle 1 DLT evaluation period. After cycle 2 dosing, 3 patients reported dose-limiting treatment-emergent adverse events (TEAEs): grade 3 pyrexia and grade 5 hepatic failure (0.19 mg/kg), grade 4 hepatic failure and platelet count decreased (0.25 mg/kg), grade 3 nausea, grade 4 platelet and neutrophil count decreased (0.25 mg/kg). The recommended phase II dose (RP2D) was 0.064 mg/kg. Common TAK-164-related TEAEs included platelet count decreased (58.1%), fatigue (38.7%), and anemia (32.3%). There was a dose-dependent increase in TAK-164 exposure over the range, 0.032-0.25 mg/kg. TAK-164 half-life ranged from 63.5 to 159 h. One patient (0.008 mg/kg) with high baseline GCC expression had an unconfirmed partial response. CONCLUSIONS: TAK-164 appeared to have a manageable safety profile at 0.064 mg/kg. Hepatic toxicity was identified as a potential risk. The RP2D of 0.064 mg/kg was considered insufficient to derive clinical benefit; there are no plans for further clinical development. CLINICAL TRIAL REGISTRATION: NCT03449030.
|
Authors | Richard Kim, Alexis D Leal, Aparna Parikh, David P Ryan, Shining Wang, Brittany Bahamon, Neeraj Gupta, Aaron Moss, Joanna Pye, Harry Miao, Haig Inguilizian, James M Cleary |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 91
Issue 4
Pg. 291-300
(04 2023)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 36738333
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2023. The Authors. |
Chemical References |
- Antibodies
- Antineoplastic Agents
- Immunoconjugates
- Receptors, Enterotoxin
|
Topics |
- Adult
- Aged
- Humans
- Middle Aged
- Antibodies
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Bayes Theorem
- Dose-Response Relationship, Drug
- Gastrointestinal Neoplasms
(drug therapy, pathology)
- Immunoconjugates
(adverse effects, therapeutic use)
- Maximum Tolerated Dose
- Receptors, Enterotoxin
(metabolism)
|